Management of Depression in Mirena (LNG-IUS) Users
If a patient develops new or worsening depressive symptoms while using Mirena, the device should be removed if the patient desires, and alternative non-hormonal contraception should be offered. The evidence strongly supports a dose-dependent relationship between levonorgestrel exposure and depression risk, with symptoms typically resolving within weeks after removal.
Evidence for the Association
The relationship between Mirena and depression is increasingly well-established:
Dose-dependent risk: A 2024 Danish national cohort study of 149,200 women demonstrated that high-dose LNG-IUS users (like Mirena 52mg) had a 52% increased risk of incident depression compared to low-dose users (RR: 1.52,95% CI: 1.30-1.74), with 1-year absolute risk of 1.84% 1. This dose-response relationship strengthens the causal inference.
Symptom onset and reversibility: Depression typically develops within 3 months of insertion 2. Critically, symptoms resolve within weeks after device removal in all documented cases 2.
Broader evidence: A 2023 systematic review found that while data quality varies, many studies report psychiatric symptoms associated with LNG-IUDs, predominantly depression and concerning reports of suicidality 3.
Clinical Management Algorithm
Step 1: Assess Temporal Relationship
- Determine when depressive symptoms began relative to Mirena insertion
- Symptoms appearing within 3 months of insertion are highly suggestive of device-related depression 2
Step 2: Explore Patient Goals
Following the 2024 CDC contraceptive guidelines framework 4:
If patient wants to continue Mirena:
- Provide counseling about the established association between LNG-IUS and depression
- Explain that symptoms are unlikely to improve while device remains in place
- Consider trial of antidepressant therapy per standard depression management 5
- Caution: This approach may expose the patient to ongoing hormonal effects and delay symptom resolution
If patient desires removal (recommended approach):
- Remove the device promptly
- Counsel that symptom improvement typically occurs within weeks 2
- Offer alternative contraceptive methods, prioritizing non-hormonal options (copper IUD, barrier methods)
- If hormonal contraception is still desired, note that some patients tolerate different progestin formulations after recovery 2, though this carries risk of recurrence
Step 3: Rule Out Other Causes
While pursuing removal, evaluate for:
- Pre-existing or family history of depression (though this does not exclude device-related worsening)
- Other medical conditions (thyroid disorders, anemia from bleeding changes)
- Psychosocial stressors
- Medication interactions
Step 4: Post-Removal Monitoring
- Follow up within 2-4 weeks after removal to assess symptom trajectory
- If symptoms persist beyond 4-6 weeks post-removal, treat as primary depression 5
- Document the adverse event
Critical Pitfalls to Avoid
Do not dismiss the patient's concerns: The association between LNG-IUS and depression is supported by high-quality observational data, including a dose-response relationship 1. While observational studies cannot prove causation definitively, the consistency of findings and rapid symptom resolution after removal support a causal relationship.
Do not delay removal in symptomatic patients who request it: The 2024 CDC guidelines explicitly state that if a patient desires removal at any time, the method should be removed 4. Symptom resolution is typically rapid after removal 2.
Do not assume all progestins will cause the same reaction: While cross-reactivity can occur (three of seven patients in one series had experienced mood problems with another progestin 2), two patients successfully used different progestin methods after recovery. However, non-hormonal options should be prioritized.
Be aware of severe presentations: One case report documented cognitive symptoms severe enough to mimic frontotemporal dementia, which resolved after LNG-IUS removal 6. While rare, this illustrates the potential severity of neuropsychiatric effects.
Special Considerations
Adolescents and young women: The depression risk appears higher in younger users, with one study reporting HR of 1.97 in this population 7. Exercise particular caution and close monitoring in this age group.
Pre-existing mental health conditions: Recent evidence suggests that women with established mood disorders may actually tolerate hormonal contraception better than previously thought, with some studies showing stable or improved symptoms 8. However, new-onset or worsening symptoms still warrant device removal if desired by the patient.
Suicidality concerns: Multiple studies have reported associations with suicidal ideation 3, 7. Any suicidal thoughts warrant immediate psychiatric evaluation and strong consideration for device removal.